Penned byfor Cannabis Business executive at
Highlights the growing pains we’ve all seen elsewhere
‘It’s California in 1995 All Over Again, Man’: Opportunities and Problems Piling Up in the European Cannabis Market
He has advised for the likes of Deutsche Telekom, The California Trade and Investment Office, Deutsche Bank, IBM & San Diego Economic Development Board
Here’s the gist of the piece
As of August, 2017 starts, the medical marijuana patients in Germany are experiencing “sold out” conditions nationwide, and the two exclusive importing countries (Canada and the Netherlands) are anticipating further bottlenecks as their in-country supply needs change. This is a significant problem – but also an opportunity for GMP-certified growers to fill the gap. If, and how, the German government opens up alternative supply to support their medical patients will be the top story in Germany this year.
From the patients perspective, there are two bad things about the current state of affairs: Little to no choice in their required medicine and their insurance companies are now refusing to cover the costs for the medicine as stipulated in the federal law.
Of course, lawyers are now getting involved and insurance companies are starting to be forced into approving valid claims from their policy-paying customers. But it is a silly, slow process to say the least.
The solution the German government is pursuing is to award 10 grow licenses to companies that will then produce 200 lbs. cannabis each within the country. The first bud from those plants are not scheduled to be picked until sometime in 2019, which is simply too long for patients to wait.